India bans 14 fixed-dose medicines for likely posing risks to health
The Indian government has banned 14 types of fixed-dose combination (FDC) medicines due to a lack of therapeutic justification and potential risks to humans, according to an expert panel's recommendations. FDCs mix two or more active ingredients i...
A FDC contains two or more active ingredients in a fixed dose ratio.
According to the government notification, the expert Committee recommended that “there is no therapeutic justification" for these FDC and they may involve "risk" to human beings.
"Hence, in the larger public interest, it is necessary to prohibit the manufacture, sale or distribution of this FDC under section 26 A of the Drugs and Cosmetics Act, 1940," the notification said.

It stated that any kind of regulation or restriction to allow for any use in patients is not "justifiable". "Therefore, only prohibition under Section 26A is recommended," it further said.
Menthol (100mg + 40mg + 2.5mg + 0.9mg) , (125mg + 55mg + 4mg + 1mg) , (110mg + 46mg + 3mg + 0.9mg) &
(130mg + 55mg + 3mg + 0.5mg) per 5ml syrup, Salbutamol + Hydroxyethyltheophylline (Etofylline) + Bromhexine.
Earlier the government had restricted about 344 categories of FDCs. However, it was challenged by various manufacturers in the court.
The Supreme Court had earlier asked the country's top technical body-DTAB to review whether these drugs should continue to be sold.
"The Central Government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition the manufacture for sale, sale and distribution for human use of the said drug in the country".
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.